Sander F. Garrelfs

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

Sander F. Garrelfs, Yaacov Frishberg, Sally A. Hulton et al. · New England Journal of Medicine · 2021 · 495 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +10

Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up

Sander F. Garrelfs, Gill Rumsby, Hessel Peters‐Sengers et al. · Kidney International · 2019 · 101 citations · Full text

Medicine, Genetics, Nephrology +14

Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria

Bernd Höppe, Annelize Koch, Pierre Cochat et al. · Kidney International · 2021 · 90 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12

A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3

Cristina Martín-Higueras, Sander F. Garrelfs, Jaap W. Groothoff et al. · Kidney International · 2021 · 53 citations · Full text

Medicine, Hematology, Internal Medicine +5

Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry

Elisabeth L. Metry, Sander F. Garrelfs, Hessel Peters‐Sengers et al. · Kidney International Reports · 2021 · 35 citations · Full text

Medicine, Nephrology, Surgery +14